Reticular Acropigmentation of Kitamura
Reticulate Acropigmentation of Kitamura ICD-9 709.09
Are You Confident of the Diagnosis?
Characteristic findings on physical examination
Reticulate (or reticular) acropigmentation of Kitamura is characterized by asymptomatic hyperpigmented macules, often with an angular or irregular shape, that first arise on the dorsal hands and feet and later develop in a more reticulate pattern on other parts of body (
Reticulate (or reticular) acropigmentation of Kitamura.
Expected results of diagnostic studies
The diagnosis is confirmed by biopsy, which shows:
Elongated rete ridges
Hypermelanosis of the basal layer
Increased number of melanocytes in basal layer
The differential diagnosis of reticular acropigmentation of Kitamura includes:
Acropigmentation of Dohi: A more common autosomal dominant disorder caused by mutations in the DSRAD gene and characterized by mottled hyperpigmentation and hypopigmentation largely confined to the dorsal hands and feet.
Dowling-Degos disease: Unlike reticular acropigmentation of Kitamura, the reticular pigmentation is centered around the flexural areas and is hyperplastic, not atrophic.
Dyschromatosis universalis hereditaria: A type of dyschromia characterized by hyperpigmented and hypopigmented macules in a generalized distribution.
Who is at Risk for Developing this Disease?
Reticular acropigmentation of Kitamura is usually inherited in an autosomal dominant fashion, though not always. The majority of reported cases have occurred in people of Asian descent. It arises in the first and second decades of life.
What is the Cause of the Disease?
The cause of reticular acropigmentation of Kitamura is unknown.
Systemic Implications and Complications
There are no reported systemic implications or complications.
1. Observation and reassurance
2. Topical options
Azelaic acid 15-20% cream or ointment applied twice daily
Tretinoin 0.02-0.1% cream apply daily
Adapalene 0.1% cream or lotion apply daily
Hydroquinone 4% cream apply twice daily
Optimal Therapeutic Approach for this Disease
Observation and reassurance is the best approach to this disease.
If the patient desires treatment, azelaic acid has been shown to be helpful in several limited case reports, so this should be considered the first-line treatment. If this fails, the relative safety of the other topical agents may lead to a therapeutic trial of one or more of the other agents for two-three months to the affected area.
There are no studies regarding the use of lasers to treatment the pigmentation. However, the Erbium:YAG laser has been used with success in the treatment of Dowling-Degos disease so use of this laser may be considered.
Patients with this rare disorder should be reassured and counseled regarding the benign nature of the disorder, the genetic implications, and the paucity of effective treatments. Routine follow-up is not necessary.
Unusual Clinical Scenarios to Consider in Patient Management
There are increasing reports of cases of reticular acropigmentation of Kitamura overlapping with Dowling-Degos disease in the same patient. This implies that the two disorders may lie on a spectrum with one another.
What is the Evidence?
Al Hawsawi, K, Al Aboud, K, Alfadley, A, Al Aboud, D. "Reticulate acropigmentation of Kitamura-Dowling Degos disease overlap: a case report". Int J Dermatol. vol. 41. 2002. pp. 518-20.(Describes a patient with features of both reticulate acropigmentation of Kitamura and Dowling-Degos disease. Discusses the likelihood that these two disorders lie on a spectrum and have similar expression.)
Gatti, S, Nini, G. "Treatment of reticulate acropigmentation of Kitamura with azelaic acid". J Am Acad Dermatol. vol. 29. 1993. pp. 666-7.(Discusses a single case of reticulate acropigmentation successfully treated with 20% azelaic acid ointment.)
Kocatürk, E, Kavala, M, Zindanci, I, Zemheri, E, Koç, MK, Sarigül, S. "Reticulate acropigmentation of Kitamura: report of a familial case". Dermatol Online J. vol. 14. 2008. pp. 7.(A single case report of a mother and daughter with familial acropigmentation of Kitamura.)
Sharma, R, Chandra, M. "Pigmentation and pits at uncommon sites in a case with reticulate acropigmentation of Kitamura". Dermatology. vol. 200. 2000. pp. 57-8.(A report of a case of reticulate acropigmentation with extensive pitting.)
Singal, A, Bhattacharya, SN, Baruah, MC, Indrayan, A, Singh, N. "Is the heredity of reticulate acropigmentation of Kitamura always autosomal dominant". J Dermatol. vol. 25. 1998 Jan. pp. 57-9.Questions the belief that acropigmentation of Kitamura is inherited in an autosomal dominant fashion. The authors report 3 families with the disorder but the inheritance pattern was clearly not autosomal dominant in all three.
Copyright © 2017, 2012 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
- Skin Cancer Screening Programs: Are They Effective?
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- Failure Rates for HPV Vaccine Higher in HIV-Positive Women, Girls
- Acrylamide in Food and Cancer Risk (Fact Sheet)
- Skin Cancer Screening Programs: Are They Effective?
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Estimating Quality of Life Based on Cumulative Drug Toxicity in Colorectal Cancer
- Communication in Shared Decision-Making in Oncology
- Hematologic Cancers: 8 Tips Oncology Nurses Should Share with Caregivers
- Culturally Sensitive Navigation Bridges Some Care Gaps for Latino Adults With Advanced Cancer
- Nedaplatin vs Cisplatin for Malignancy-Induced MPE: Noninferior, Less Toxicity
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|